Fundraising FoxInscripta
Boulder, US · Delaware corporation · 11 known investors
Find your way into Inscripta
Sign up to see every warm intro you have to Inscripta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Inscripta team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MG
Michael GraigeExecutive
RM
Ron McGrathExecutive
SK
Sri KosarajuExecutive
DL
Dianna L. DeVoreExecutive
RG
Ryan GillFounder
TL
Tanya LipscombFounder
Board
RW
BR
JR
Investors · 11
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
iGlobe Partnerslisted by iGlobe PartnersSingapore · $600K – $6M
How we know: iGlobe Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Oak HC/FTlisted by Oak HC/FTStamford
How we know: Oak HC/FT's portfolio page · funding news · Not right? Tell us
OMX Ventureslisted by OMX VenturesLincolnshire
How we know: the VCSheet dataset · Not right? Tell us
Paladin Capital Grouplisted by Paladin Capital GroupWashington · $100K – $5M
How we know: funding news · Not right? Tell us
Spruce Capital Partnerslisted by Spruce Capital PartnersSouth San Franciscovia Roger Wyse · board
How we know: board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
Venrocklisted by VenrockPalo Alto · $500K – $10M
How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Vertical Venture Partnerslisted by Vertical Venture PartnersPalo Alto · $500K – $4M
How we know: the VCSheet dataset · Not right? Tell us
Xeraya Capitallisted by Xeraya CapitalKuala Lumpur
How we know: Xeraya Capital's portfolio page · Not right? Tell us
+ND CapitalreportedWoodside · $540K – $5.4M
How we know: a partner's Signal profile · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$473.9M disclosed across 14 rounds · 2016–2022
▶$1.9MraisedJun 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Roger WyseDirector
- Kristala L. Jones PratherDirector
- Sri KosarajuExecutive Officer, Director
- Bryan RobertsDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.4MraisedJan 2023 · 4 investors · BiotechnologyRule 506(b)
▶$4.4MraisedJan 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Ron McGrathExecutive Officer
- Kristala L. Jones PratherDirector
- Sri KosarajuExecutive Officer, Director
- Roger WyseDirector
- Bryan RobertsDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.8MraisedJan 2023 · 5 investors · BiotechnologyRule 506(b)
▶$27.8MraisedJan 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron McGrathExecutive Officer
- Roger WyseDirector
- Sri KosarajuExecutive Officer, Director
- Kristala L. Jones PratherDirector
- Justin FerberExecutive Officer
- John R. StuelpnagelDirector
- Bryan RobertsDirector
- Offering amount
- $27.8M
- Amount sold
- $27.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150MraisedApr 2021 · 32 investors · BiotechnologyRule 506(b)
▶$150MraisedApr 2021 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GraigeExecutive Officer
- John R. StuelpnagelDirector
- Ron McGrathExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Roger WyseDirector
- Dianna L. DeVoreExecutive Officer
- Bryan RobertsDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedNov 2020 · 6 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dianna L. DeVoreExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Ron McGrathExecutive Officer
- Michael GraigeExecutive Officer
- Roger WyseDirector
- John R. StuelpnagelDirector
- Bryan RobertsDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$8.1MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John R. StuelpnagelDirector
- Roger WyseDirector
- Michael GraigeExecutive Officer
- Ron McGrathExecutive Officer
- Dianna L. DeVoreExecutive Officer
- Sri KosarajuExecutive Officer, Director
- Bryan RobertsDirector
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.1MraisedDec 2019 · 12 investors · BiotechnologyRule 506(b)
▶$92.1MraisedDec 2019 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ron McGrathExecutive Officer
- Jason GammackExecutive Officer
- Kevin D. NessExecutive Officer, Director
- Michael GraigeExecutive Officer
- Dianna DeVoreExecutive Officer
- Tanya LipscombPromoter
- Bryan RobertsDirector
- John R. StuelpnagelDirector
- Roger WyseDirector
- Andrew D. GarstPromoter
- Ryan T. GillPromoter
- Offering amount
- $125M
- Amount sold
- $92.1M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$50MraisedApr 2019 · 14 investors · BiotechnologyRule 506(b)
▶$50MraisedApr 2019 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D. NessExecutive Officer, Director
- Dianna DeVoreExecutive Officer
- Bryan RobertsDirector
- John R. StuelpnagelDirector
- Jason GammackExecutive Officer
- Andrew D. GarstPromoter
- Ryan T. GillPromoter
- Tanya LipscombPromoter
- Michael GraigeExecutive Officer
- Roger WyseDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Inscripta went on to found or lead other companies.
Related companies · 5
Scribe TherapeuticsScribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Predicta BiosciencesPredicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.
Transcripta BioTranscripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution. Its drug discovery platform draws on single-cell genomics and AI for biology.
Manus BioManus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing. Its products include sweeteners and flavor/fragrance ingredients supplied to food and consumer goods companies such as Tate & Lyle and Givaudan.
SepternaSepterna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
Companies working in the same space as Inscripta.
Acquisitions · 1
Early investors' stakes continue via these dealsSestina Bio
Sestina Bio was a Pleasanton, California synthetic-biology company that used single-cell genome editing and machine learning to engineer yeast and bacteria strains for scalable production of chemicals, ingredients, and pharmaceuticals.
In the news
Frequently asked questions
- Who are Inscripta's investors?
- Inscripta's investors include Foresite Capital, iGlobe Partners, Korys, Oak HC/FT, OMX Ventures, Paladin Capital Group, Spruce Capital Partners, Venrock and 3 more.
- How much funding has Inscripta raised?
- Inscripta has disclosed $473.9M raised across 14 rounds.
- Where is Inscripta headquartered?
- Inscripta is headquartered in Boulder, US.